Researchers at Baylor College of Medicine and Rice University have received a $2.3 million Breakthrough Award from the ...

Linda D’Addario, a cancer survivor, now mentors others through Cancer Hope Network, a program now available at five area ...

Olema Oncology plans to start a Phase III trial studying palazestrant with a CDK4/6 inhibitor from Novartis in mid-2025.

The phase 1/2 study will assess next-generation immunotherapy alone and in combination with an immune checkpoint inhibitor in ...

Flatiron Health today announced their planned presence at this year’s San Antonio Breast Cancer Symposium (SABCS), including four accepted abstracts for poster presentation and a Flatiron ...

The Data Safety Monitoring Board (DSMB) stated no safety concerns, and recommended continuation of BriaCell’s pivotal Phase 3 study of Bria-IMT™ ...

An expert discusses the next steps for patients with metastatic breast cancer after their disease no longer responds to ...

On Nature published the results of an innovative breast cancer research project from the Netherlands. This study, the SONIA ...

Barbara O’Brien, MD, discusses the next steps of the phase 2 TBCRC049 study for the treatment of patients with HER2-positive ...

Top Forbes | SHOOK financial advisors and Wall Street investment firms have pledged more than $500,000 toward development of ...

The "Metastatic Triple-Negative Breast Cancer (mTNBC)- Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.This report provides comprehensive insights about 10+ ...

Olema Pharmaceuticals, Inc. (OLMA), a clinical-stage biopharmaceutical company, Monday announced a new clinical trial collaboration ...